Editing the human genome has been a stand-by in sci-fi movies for decades. But Crispr—the relatively easy and inexpensive editing technique, with emphasis on relatively—has led many to believe such a disease-curing technology is within reach.
To see Crispr's real abilities in solving otherwise difficult medical problems, scientists may need to look at blood disorders.
As the article in Wired says, "Plenty of gene-editing techniques have been attempted as therapies, but few have made significant impacts—especially when it comes to diseases as complex as cancer. A better place to start testing gene therapies is with inherited blood disorders, like sickle cell anemia and beta thalassemia."
Check out the full article below:
Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.